Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults
Authors
Keywords
-
Journal
JOURNAL OF INFECTIOUS DISEASES
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2019-05-18
DOI
10.1093/infdis/jiz241
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV∆G-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak
- (2018) Mohamed Samai et al. JOURNAL OF INFECTIOUS DISEASES
- Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
- (2018) Angela Huttner et al. LANCET INFECTIOUS DISEASES
- A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus
- (2018) Bronwyn M. Gunn et al. Cell Host & Microbe
- Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea
- (2018) Aitana Juan-Giner et al. VACCINE
- Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults
- (2017) Scott A. Halperin et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)
- (2017) Ana Maria Henao-Restrepo et al. LANCET
- Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study
- (2017) D Gray Heppner et al. LANCET INFECTIOUS DISEASES
- A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
- (2017) Jason A. Regules et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia
- (2017) Stephen B. Kennedy et al. NEW ENGLAND JOURNAL OF MEDICINE
- After Ebola in West Africa — Unpredictable Risks, Preventable Epidemics
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
- (2016) Selidji T. Agnandji et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial
- (2015) Ana Maria Henao-Restrepo et al. LANCET
- The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
- (2015) Angela Huttner et al. LANCET INFECTIOUS DISEASES
- VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain
- (2015) A. Marzi et al. SCIENCE
- Ebola virus vaccines: an overview of current approaches
- (2014) Andrea Marzi et al. Expert Review of Vaccines
- Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates
- (2013) A. Marzi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates
- (2012) Chad E. Mire et al. PLoS Neglected Tropical Diseases
- Vesicular Stomatitis Virus–Based Ebola Vaccines With Improved Cross-Protective Efficacy
- (2011) Andrea Marzi et al. JOURNAL OF INFECTIOUS DISEASES
- Ebola haemorrhagic fever
- (2010) Heinz Feldmann et al. LANCET
- Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses
- (2009) Xiangguo Qiu et al. PLoS One
- Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates
- (2008) Thomas W. Geisbert et al. PLoS Pathogens
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search